SIGNATURE ESTATE & INVESTMENT ADVISORS LLC
Position in NVO — Novo Nordisk A S
CIK 1079935
LOS ANGELES, CA
Position in NVO
as of Jun 30, 2026
· filed Jul 14, 2026
Position Value
$422,350
+$56,394 QoQ
Shares Held
8,810
-11.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#764
of 1,348 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SIGNATURE ESTATE & INVESTMENT ADVISORS LLC holds $78,743,107 across 9 Drug Manufacturers - General names. NVO ranks #8 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
57,559 | $69,037,996 | |
| 2 | JNJ |
Johnson & Johnson
|
8,972 | $2,278,618 | |
| 3 | AMGN |
Amgen Inc
|
6,232 | $2,256,731 | |
| 4 | ABBV |
AbbVie Inc.
|
5,312 | $1,336,711 | |
| 5 | AZN |
Astrazeneca PLC
|
6,802 | $1,289,794 | |
| 6 | PFE |
Pfizer Inc
|
38,803 | $934,375 | |
| 7 | MRK |
Merck & Co., Inc.
|
7,229 | $928,926 | |
| 8 | NVO |
Novo Nordisk A S
This page
|
8,810 | $422,350 |
All Filings in NVO
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $422,350 | 8,810 | Shares | Sole | 2026-07-14 | |
| 2026-03-31 | $365,956 | 9,958 | Shares | Defined | 2026-04-15 | |
| 2025-12-31 | $374,730 | 7,365 | Shares | Defined | 2026-02-06 | |
| 2025-09-30 | $433,542 | 7,813 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $552,297 | 8,002 | Shares | Sole | 2025-07-29 | |
| 2025-03-31 | $570,865 | 8,221 | Shares | Sole | 2025-05-16 | |
| 2024-12-31 | $541,581 | 6,296 | Shares | Defined | 2025-02-11 | |
| 2024-09-30 | $736,447 | 6,185 | Shares | Sole | 2024-11-06 | |
| 2024-06-30 | $875,995 | 6,137 | Shares | Sole | 2024-07-26 | |
| No filing history on record for this holder in this stock. | ||||||